EMA Approves Use of Sotrovimab to Treat COVID-19
The agency’s human medicines committee concluded sotrovimab can be used to treat COVID-19 in adults and adolescents who do not require supplemental oxygen therapy and are at risk for severe COVID-19.
The European Medicines Agency (EMA) announced on May 21, 2021 that its human medicines committee (CHMP) reviewed available data and determined that sotrovimab can be used to treat COVID-19 in adults and adolescents who do not require supplemental oxygen therapy and are at risk for severe COVID-19. A rolling review of sotrovimab began on May 7, 2021 and is ongoing.
CHMP reviewed quality data and data from a study of the effects of sotrovimab in adult outpatients with mild COVID-19 symptoms. “A planned interim analysis of this study indicated that sotrovimab reduced the risk of hospitalization for more than 24 hours or death by 85% compared with placebo: hospitalization for more than 24 hours or death occurred in 1% (3 out of 291) of patients who received sotrovimab and 7% (21 out of 292) of those who received placebo,” the agency stated in a press release.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
